Carl G F, Smith D B
Biochem Pharmacol. 1984 Nov 1;33(21):3457-63. doi: 10.1016/0006-2952(84)90120-5.
Chronic oral phenobarbital treatment (50 mg/kg every 12 hr for 8 weeks), which was nontoxic and continuously protective against seizures in rats, significantly decreased folate concentration in liver (29%) but not in brain or plasma. The apparent activity of 5,10-methylenetetrahydrofolate reductase (MTR) in liver decreased with initiation of treatment but then increased with a significant correlation to the length of treatment. Phenobarbital also stimulated the activity of this enzyme slightly in vitro. Methionine adenosyltransferase (MAT) activity was inhibited by high concentrations of phenobarbital in vitro but was not affected in vivo. No significant effects of phenobarbital on the activities of serine hydroxymethyltransferase (SHMT) or 5-methyltetrahydrofolate:homocysteine methyltransferase (MHMT) were observed either in vivo or in vitro.
慢性口服苯巴比妥治疗(每12小时50毫克/千克,持续8周)对大鼠无毒且能持续预防癫痫发作,该治疗显著降低了肝脏中的叶酸浓度(29%),但对脑或血浆中的叶酸浓度没有影响。随着治疗开始,肝脏中5,10-亚甲基四氢叶酸还原酶(MTR)的表观活性降低,但随后增加,且与治疗时长呈显著相关。苯巴比妥在体外也能轻微刺激该酶的活性。蛋氨酸腺苷转移酶(MAT)的活性在体外受到高浓度苯巴比妥的抑制,但在体内不受影响。无论是在体内还是体外,均未观察到苯巴比妥对丝氨酸羟甲基转移酶(SHMT)或5-甲基四氢叶酸:同型半胱氨酸甲基转移酶(MHMT)的活性有显著影响。